Clinical Trials
Several clinical trials have evaluated IRAK4-related inflammatory conditions. A completed observational study, sponsored by Kymera Therapeutics Inc. and the York Dermatology Clinic and Research Centre, evaluated cutaneous and circulating inflammatory biomarkers in hidradenitis suppurativa and atopic dermatitis. Additionally, an unassigned-phase study with unknown recruitment status, supported by Queen Fabiola Children's University Hospital and the Belgium Kid's Fund, investigated sex differences in immune responses and pediatric acute inflammatory diseases.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04440410 | Completed | Hidradenitis Suppurativa|Dermatitis Atopic |
Kymera Therapeutics Inc.|York Dermatology Clinic and Research Centre |
2020-05-28 | -- |
| NCT04815811 | Unknown status | Sex Differences in Immune Response|Acute Inflammatory Diseases in Children |
Queen Fabiola Children''s University Hospital|Belgium Kid''s Fund |
2019-08-17 | Not Applicable |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).